Clinical Trials Logo

Clinical Trial Summary

The current standard for recurrent, persistent or metastatic cervical cancer is palliative chemotherapy with cisplatin topotecan, however, the results need to be improved. Epigenetic aberrations play an important role in cancer progression by silencing growth regulatory genes and there is now evidence that inhibitors of DNA methylation and HDAC inhibition synergize the cytotoxicity of chemotherapy.

Objective. To determine the superiority of epigenetic therapy with hydralazine and valproate plus standard cisplatin topotecan against placebo plus cisplatin topotecan upon progression-free survival.

Hypothesis. Hydralazine and magnesium valproate associated to cisplatin topotecan will increase progression-free survival from 4.6 to 7.6 months as compared with the same regimen of chemotherapy plus placebo.


Clinical Trial Description

Randomized, double-blind phase III trial. A total of 143 patients (alpha 0.5, power 0.8)with metastatic, persistent or recurrent cervical cancer without previous systemic treatment will be randomized to cisplatin topotecan + placebo or cisplatin topotecan hydralazine valproate for 6 courses every 3 weeks. Patients will receive an oral dose of hydralazine of 182mg (rapid) or 83mg (slow) according to the acetylator phenotype in a single daily dose and magnesium valproate at an oral dose of 40mg/Kg t.i.d. Both drugs in a slow-release formulation. Experimental drugs or placebo will start from seven days before day 1 of chemotherapy until the end of the sixth course. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00532818
Study type Interventional
Source National Institute of Cancerología
Contact Alfonso Dueñas-Gonzalez, MD PhD
Phone +5255 56280486
Email alfonso_duenasg@yahoo.com
Status Recruiting
Phase Phase 3
Start date July 2007
Completion date December 2010

See also
  Status Clinical Trial Phase
Recruiting NCT05446883 - QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer Phase 3
Active, not recruiting NCT04266886 - Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer N/A
Recruiting NCT04865887 - Pembrolizumab and Lenvatinib in Advanced Cervical Cancer Phase 2
Completed NCT00430781 - Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer Phase 2
Terminated NCT03786107 - HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib
Recruiting NCT06238635 - Dostarlimab and Cobolimab in Advanced Cervical Cancer Phase 2
Recruiting NCT06157151 - PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer Phase 2
Withdrawn NCT05614453 - Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy Phase 2
Terminated NCT03277482 - Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer Phase 1
Completed NCT04380805 - A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer Phase 2
Completed NCT03816553 - SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer Phase 2
Withdrawn NCT04943627 - Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) Phase 3
Recruiting NCT06313268 - Safety of Effivia®, a Bevacizumab Biosimilar
Terminated NCT04230954 - Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer Phase 2